SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT02122211

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Choline Dehydrogenase and Sperm Function: Effects of Betaine

The ability of sperm to swim is important for normal fertility. Men with a genetic variation in the gene coding for Choline Dehydrogenase (CHDH) have decreased energy production by sperm, and their sperm do not swim normally. The metabolic product of this gene is a nutrient called betaine (found normally in the diet as a part of many foods such as spinach, beets and grain products). This study tests whether treatment with betaine is safe and whether it can normalize energy production in sperm of these men and restore normal swimming ability.

NCT02122211 Men Carrying 2 Minor Alleles for Choline Dehydrogenase rs12676 Male Infertility
MeSH: Infertility Infertility, Male
HPO: Infertility Male infertility

1 Interventions

Name: Betaine supplement

Type: Drug

Betaine supplement


Primary Outcomes

Description: Assessed using Computer-Aided Sperm Analysis methodology

Measure: Change in sperm motility from baseline

Time: On day zero, day 10, day 30, day 50 and at the end of the 75 day treatment period

Measure: Change in sperm count from baseline

Time: On day zero, day 10, day 30, day 50 and at the end of the 75 day treatment period

Description: Using Seahorse biochemical function assessment

Measure: Change in sperm mitochondrial function from baseline

Time: On day zero, day 10, day 30, day 50 and at the end of the 75 day treatment period

Description: Using light and transmission electron microscopy

Measure: Change in sperm ultrastructure from baseline

Time: On day zero, day 10, day 30, day 50 and at the end of the 75 day treatment period

Description: Assessed by Western Blot analysis

Measure: Change in sperm choline dehydrogenase concentration from baseline

Time: On day zero, day 10, day 30, day 50 and at the end of the 75 day treatment period

Measure: Change in sperm betaine concentration from baseline

Time: On day zero, day 10, day 30, day 50 and at the end of the 75 day treatment period

Secondary Outcomes

Description: Assessed using 3-day food records

Measure: Betaine intake

Time: At screening and every 21 days during the study

Measure: Change in complete blood count from baseline

Time: At 0, 10, 30, 50, and 75 days on treatment

Measure: Change in uric acid concentration from baseline

Time: At 0, 10, 30, 50, and 75 days on treatment

Measure: Change in alkaline phosphatase concentration from baseline

Time: At 0, 10, 30, 50, and 75 days on treatment

Measure: Change in aspartate transaminase concentration from baseline

Time: At 0,10, 30, 50, and 75 days on treatment

Measure: Change in lactic dehydrogenase concentration from baseline

Time: At 0, 10, 30, 50, and 75 days on treatment

Measure: Change in bilirubin concentration from baseline

Time: At 0, 10, 30, 50, and 75 days on treatment

Measure: Change in blood urea nitrogen concentration from baseline

Time: At 0, 10, 30, 50, and 75 days on treatment

Measure: Change in creatinine concentration from baseline

Time: At 0, 10, 30, 50, and 75 days on treatment

Measure: Change in urinalysis parameters from baseline

Time: At 0, 10, 30, 50, and 75 days on treatment

Purpose: Basic Science

Single Group Assignment


There is one SNP

SNPs


1 rs12676

Inclusion Criteria: - 18 - 60 year old men of multiple races and ethnicities - Estimated dietary intake of betaine of <150 mg/day - Carrying two alleles of the rs 12676 single nucleotide polymorphism Exclusion Criteria: - Cystathionine-beta-synthase (CBS) deficiency - Currently taking betaine supplements - Currently receiving chemotherapy, radiation or any gonadotoxic drug - Female gender Inclusion Criteria: - 18 - 60 year old men of multiple races and ethnicities - Estimated dietary intake of betaine of <150 mg/day - Carrying two alleles of the rs 12676 single nucleotide polymorphism Exclusion Criteria: - Cystathionine-beta-synthase (CBS) deficiency - Currently taking betaine supplements - Currently receiving chemotherapy, radiation or any gonadotoxic drug - Female gender Men Carrying 2 Minor Alleles for Choline Dehydrogenase rs12676 Male Infertility Infertility Infertility, Male Unidentified genetic aberrations such as single nucleotide polymorphisms (SNPs) may be the underlying cause of many cases of idiopathic infertility in men.

5-9% of men have 2 alleles for a functional SNP in CHDH (rs12676), and they have low sperm adenosine triphosphate (ATP) concentrations with impaired sperm motility (asthenospermia) that should decrease fertility.

This purpose of this study is to conduct a phase I study of betaine treatment in men with 2 minor alleles for CHDH rs12676 to determine whether betaine supplementation is safe and to obtain preliminary data on the effects of betaine on sperm mitochondrial ATP concentrations and sperm motility in these men.



HPO Nodes


HPO:
Infertility
Genes 133
HJV MKRN3 SOX3 SNORD115-1 SOX9 AMH PATL2 PLCZ1 AMHR2 KLHL10 WDR66 MAGEL2 CFAP300 SRA1 ZMPSTE24 WWOX LHX4 GCM2 STUB1 DNAAF4 TUBB8 AXL DAZ4 CYP19A1 RBMY1A1 CFTR DUSP6 TSGA10 GATA4 WT1 MEIOB CCNO IPW PWRN1 CDH23 POU1F1 SRY DAZ1 NDN LRRC6 CFAP43 TSPY1 H6PD HUWE1 TEX14 NR3C1 USP9Y TEX11 CCDC141 GBA2 ZP3 QRICH2 CFAP298 CDC14A AR CCDC39 AK7 SNORD116-1 HESX1 FGF17 MAP3K1 ZFPM2 PGR MKRN3-AS1 DNAH1 FANCA DNAJB13 LHCGR ZP1 FSIP2 DNAAF5 DNAAF3 DNAI1 AURKC USP8 SLC26A8 PTPN11 OTX2 POLR3B CATSPER1 FOXL2 DMRT3 DHH LMNA BRAF CATSPER2 BRDT ZMYND10 RSPH1 ADGRG2 WDR11 FEZF1 GLI2 SPATA16 FSHB SPRY4 VAMP7 NR0B1 SUN5 DNAI2 NPAP1 TLE6 SOHLH1 RNF216 DDX3Y PIH1D3 WEE2 NR5A1 FLRT3 CTNS PWAR1 STRC HERC2 HSD17B3 DAZ3 DAZ2 DNAAF1 PLIN1 CFAP44 MAP2K1 IL17RD DNAH9 NANOS1 GNRH1 GNRHR SNRPN PRLR SEPTIN12 PMFBP1 CEP19 PROP1 SEMA3E CCDC40
Male infertility
Genes 41
GATA4 WT1 LHCGR SOX9 DNAAF5 DNAI1 AURKC AMH AMHR2 DDX3Y SRY DAZ1 NR5A1 PTPN11 CTNS CATSPER1 TSPY1 STRC DMRT3 WWOX DAZ3 USP9Y GCM2 TEX11 DAZ2 BRAF CATSPER2 MAP2K1 ADGRG2 DAZ4 CYP19A1 RBMY1A1 MAP3K1 ZFPM2 CFTR PMFBP1 VAMP7 NR0B1 SUN5 DNAI2 FANCA